journal article·2022-09-19

Cyclodextrin-based gefitinib nanobubbles for synergistic apoptosis in lung cancer

Drashti Desai, Pravin Shende

Materials Technology· Volume 37· Issue 11
Publisher page

Abstract

The present research work aimed to develop and characterize nanobubbles (NBs) for synergistic action in human cell line A549 using gefitinib and oxygen. NBs were prepared by loading oxygen in β-cyclodextrin-based inclusion complex (IC), whereas in nanosponges by polymer condensation method. Initially, the amino-functionalization was performed using (3-aminopropyl) triethoxysilane and then, underwent PEGylation to achieve site-specific action. The loading capacities of PEGylated and non-PEGylated NBs of gefitinib were found to be 85.11 ± 2.31% and 86.14±1.24%, respectively, whereas oxygen levels were found to be 2.8mg/L and 6.9mg/L, respectively. The synergistic effect of gefitinib NBs was observed by flow cytometry due to apoptosis of cell line A549 (with apoptotic rate ranged from 35.2±2.15% to 73.6±1.57%) by inhibiting EGFR pathway and further confirmed using western blotting technique. Dual delivery of gefitinib and oxygen from β-cyclodextrin-based nanosponges showed that NBs act as a novel therapy in the treatment of non-small cell lung cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic and Hepatic Oncology Research · Minerals Flotation and Separation Techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

SVKM’S NMIMS

References (56)

Show source-provided references
1. 10.1038/srep4402110.1038/srep44021 ↗
2. 10.1038/nrc208810.1038/nrc2088 ↗
3. 10.1038/s41571-018-0081-410.1038/s41571-018-0081-4 ↗
4. 10.1097/JTO.000000000000003310.1097/JTO.0000000000000033 ↗
5. 10.1016/S0140-6736(16)00004-010.1016/S0140-6736(16)00004-0 ↗
6. 10.1056/NEJMoa090455410.1056/NEJMoa0904554 ↗
7. 10.1634/theoncologist.2008-001910.1634/theoncologist.2008-0019 ↗
8. 10.1038/nrd287110.1038/nrd2871 ↗
9. 10.1038/s41388-018-0454-210.1038/s41388-018-0454-2 ↗
10. 10.3322/caac.2007310.3322/caac.20073 ↗
11. 10.1016/1040-8428(94)00144-I10.1016/1040-8428(94)00144-I ↗
12. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379–2385.
13. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):1–27.
14. 10.1016/S0093-7754(03)70010-410.1016/S0093-7754(03)70010-4 ↗
15. 10.1053/j.seminoncol.2005.10.00410.1053/j.seminoncol.2005.10.004 ↗
16. 10.4103/0976-9668.18469510.4103/0976-9668.184695 ↗
17. 10.1038/s41556-018-0118-z10.1038/s41556-018-0118-z ↗
18. 10.1038/ncomms658210.1038/ncomms6582 ↗
19. 10.1128/MCB.23.1.359-369.200310.1128/MCB.23.1.359-369.2003 ↗
20. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 1998;58(16):3547–3550.
21. 10.1038/bjc.1998.3810.1038/bjc.1998.38 ↗
22. 10.1615/CritRevTherDrugCarrierSyst.201802022910.1615/CritRevTherDrugCarrierSyst.2018020229 ↗
23. 10.1038/s41598-017-08988-710.1038/s41598-017-08988-7 ↗
24. 10.1126/scitranslmed.aaa126010.1126/scitranslmed.aaa1260 ↗
25. 10.1371/journal.pone.012747110.1371/journal.pone.0127471 ↗
26. 10.1016/j.pharmthera.2015.06.00610.1016/j.pharmthera.2015.06.006 ↗
27. 10.1007/s10847-011-9926-510.1007/s10847-011-9926-5 ↗
28. Trotta F, Zanetti M, Cavalli R. Beilstein, Cyclodextrin-based nanosponges as drug carriers. J Org Chem. 2012;8:2091–2099.
29. Cramer F, Henglein FM. Einschlussverbindungen der cyclodextrine mit gasen. Angew Chem. 1956;68(20):649.10.1002/ange.19560682008 ↗
30. 10.18632/oncotarget.1815510.18632/oncotarget.18155 ↗
31. 10.3389/fphar.2019.0061010.3389/fphar.2019.00610 ↗
32. 10.1016/j.actbio.2020.03.03410.1016/j.actbio.2020.03.034 ↗
33. Wang JP, Yan JP, Xu J, et al. Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer. Cancer Mang Res. 2019;11:6637.
34. 10.1016/j.ijpharm.2019.05.03910.1016/j.ijpharm.2019.05.039 ↗
35. 10.1007/s10847-012-0140-x10.1007/s10847-012-0140-x ↗
36. Desai D, Shende P. Drug-free cyclodextrin-based SP. Nanosponges for antimicrobial activity. J Pharm Innov. 2020;16 (2): 258-268.
37. 10.1002/jps.2441610.1002/jps.24416 ↗
38. Hengrui Z, Wen S, Zhang Y, et al. Polyethylene Glycol functionalized magnetic mesoporous silica nanoparticles as carriers for CpG Immunotherapy In vitro and In vivo. PLOS One. 2015;10(10):1–17.
39. Sadjadi S, Heravi M, Daraie M. Cyclodextrin nanosponges: a potential catalyst and catalyst support for synthesis of xanthenes. Res Chem Intermediat. 2016;43(2):1–15.
40. 10.1016/j.colsurfb.2015.09.00210.1016/j.colsurfb.2015.09.002 ↗
41. Stieger N, Liebenberg W, Wessels JC. UV spectrophotometric method for the identification and solubility determination of nevirapine. Pharmazie. 2009;64(10):690–691.
42. 10.3389/fphar.2019.0100110.3389/fphar.2019.01001 ↗
43. 10.3892/ol.2016.460610.3892/ol.2016.4606 ↗
44. 10.1371/journal.pone.001869110.1371/journal.pone.0018691 ↗
45. 10.1016/j.msec.2017.03.18410.1016/j.msec.2017.03.184 ↗
46. MDA S, Martínez-Monteagudo SI. Oxidative stability of fats and oils measured by differential scanning calorimetry for food and industrial applications. In: Appl calorim a wide context-differ scanning calorimetry, isothermal titration calorim microcalorim. mal Ali Elkordy, University of Sunderland, United Kingdom. IntechOpen. 2013: 445-474.
47. 10.1016/B978-0-12-800173-8.00005-210.1016/B978-0-12-800173-8.00005-2 ↗
48. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
49. 10.1007/s11095-015-1771-610.1007/s11095-015-1771-6 ↗
50. 10.1590/S1984-8250201100040000310.1590/S1984-82502011000400003 ↗
51. Makoid MC, Dufour A, Banakar UV. Modelling of dissolution behaviour of controlled release system. STP pharma pratiques. 1993;3:49.
52. Zheng W, Liu T, Sun R, et al. Daidzein induces choriocarcinoma cell apoptosis in a dose-dependent manner via the mitochondrial apoptotic pathway. Mol Med Rep. 2018;17(4):6093–6099.
53. 10.1038/srep0749010.1038/srep07490 ↗
54. 10.1101/cshperspect.a01698010.1101/cshperspect.a016980 ↗
55. 10.1016/j.ajps.2019.06.00110.1016/j.ajps.2019.06.001 ↗
56. 10.1111/j.1582-4934.2011.01337.x10.1111/j.1582-4934.2011.01337.x ↗